Literature DB >> 10414909

Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose.

D A Stewart1, D Guo, J Luider, I Auer, J Klassen, E Ching, D Morris, A Chaudhry, C Brown, J A Russell.   

Abstract

Data were analyzed on 178 consecutive patients (median age 43 years) who underwent autologous blood stem cell transplantation (ABSCT) at a single institution to determine if CD34+ subsets (CD34+38-, CD34+33-, CD34+33+, CD34+41+) or various clinical factors affect hematopoietic engraftment independent of the total CD34+ cell dose/kg. Using Cox proportional hazards models, the factors independently associated with rapid neutrophil engraftment were higher CD34+ dose/kg, use of G-CSF post-ABSCT, and conditioning regimen (single-agent melphalan +/- TBI slower). Factors independently associated with rapid platelet engraftment were higher CD34+ cell dose/kg, higher ratio of CD34+33-/total CD34+ cells infused, conditioning regimen (mitoxantrone, vinblastine, cyclophosphamide faster), and no CD34+ cell selection of the autograft. The CD34+ cell selection process seemed to deplete CD34+41+ cells to a greater extent than total CD34+ cells which may explain our observation that it resulted in slower platelet engraftment. In conclusion, the total CD34+ dose/kg was a better predictor of hematopoietic engraftment following ABSCT than the dose of any CD34+ subset. Platelet engraftment, however, was also influenced by the ratio of CD34+33-/total CD34+ cells for unmanipulated autografts, and possibly by the CD34+41+ dose for autografts manipulated by CD34+ selection. The use of CD34+ subsets requires further investigation in predicting engraftment of autografts which undergo ex vivo manipulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10414909     DOI: 10.1038/sj.bmt.1701800

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory.

Authors:  Gregory J Pomper; Emily Wilson; Scott Isom; David D Hurd
Journal:  Transfusion       Date:  2010-12-22       Impact factor: 3.157

3.  Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Authors:  Elad Ziv; Eric Dean; Donglei Hu; Alessandro Martino; Daniel Serie; Karen Curtin; Daniele Campa; Blake Aftab; Paige Bracci; Gabriele Buda; Yi Zhao; Jennifer Caswell-Jin; Robert Diasio; Charles Dumontet; Marek Dudziński; Laura Fejerman; Alexandra Greenberg; Scott Huntsman; Krzysztof Jamroziak; Artur Jurczyszyn; Shaji Kumar; Djordje Atanackovic; Martha Glenn; Lisa A Cannon-Albright; Brandt Jones; Adam Lee; Herlander Marques; Thomas Martin; Joaquin Martinez-Lopez; Vincent Rajkumar; Juan Sainz; Annette Juul Vangsted; Marzena Wątek; Jeffrey Wolf; Susan Slager; Nicola J Camp; Federico Canzian; Celine Vachon
Journal:  Nat Commun       Date:  2015-07-22       Impact factor: 14.919

4.  Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells.

Authors:  Kian-Ngiap Chua; Chou Chai; Peng-Chou Lee; Seeram Ramakrishna; Kam W Leong; Hai-Quan Mao
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

Review 5.  An osteoconductive, osteoinductive, and osteogenic tissue-engineered product for trauma and orthopaedic surgery: how far are we?

Authors:  Wasim S Khan; Faizal Rayan; Baljinder S Dhinsa; David Marsh
Journal:  Stem Cells Int       Date:  2011-10-25       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.